BioScrip (NASDAQ: BIOS) is one of 15 publicly-traded companies in the “Hospitals, Clinics & Primary Care Services” industry, but how does it compare to its rivals? We will compare BioScrip to similar businesses based on the strength of its valuation, analyst recommendations, dividends, earnings, profitability, risk and institutional ownership.
This table compares BioScrip and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk & Volatility
BioScrip has a beta of 0.27, indicating that its stock price is 73% less volatile than the S&P 500. Comparatively, BioScrip’s rivals have a beta of 0.87, indicating that their average stock price is 13% less volatile than the S&P 500.
Institutional & Insider Ownership
84.7% of BioScrip shares are owned by institutional investors. Comparatively, 69.6% of shares of all “Hospitals, Clinics & Primary Care Services” companies are owned by institutional investors. 0.8% of BioScrip shares are owned by insiders. Comparatively, 10.8% of shares of all “Hospitals, Clinics & Primary Care Services” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
This is a summary of current ratings and target prices for BioScrip and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
BioScrip currently has a consensus target price of $3.75, suggesting a potential upside of 42.05%. As a group, “Hospitals, Clinics & Primary Care Services” companies have a potential upside of 17.60%. Given BioScrip’s stronger consensus rating and higher probable upside, research analysts clearly believe BioScrip is more favorable than its rivals.
Earnings & Valuation
This table compares BioScrip and its rivals revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|BioScrip||$935.59 million||-$41.50 million||-3.88|
|BioScrip Competitors||$1.06 billion||-$22.56 million||780.70|
BioScrip’s rivals have higher revenue and earnings than BioScrip. BioScrip is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
BioScrip rivals beat BioScrip on 8 of the 12 factors compared.
BioScrip, Inc. is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment. The Company operates through approximately 70 service locations in over 30 states. The Company offers home infusion services to provide clinical management services and the delivery of prescription medications. The Company provides services in coordination with, and under the direction of, the patient’s physician. The Company’s multidisciplinary team of clinicians, including pharmacists, nurses, dietitians and respiratory therapists, work with the physician to develop a plan of care suited to the patient’s specific needs. Its platform provides service capabilities to deliver clinical management services that offer patients a community-based and home-based care environment.
Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.